Healthcare / Diagnostics & ResearchLSE
$0.18
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-9.0M · quality 38.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-999.4%
↓Gross Margin
47.7%
↓Debt/Equity
4.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+92.3%
FCF CAGR
—
FCF margin
-713.9%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.1M · net income $-11.2M · FCF $-7.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1M | $1.1M | $636000.00 | $510000.00 | $154000.00 |
| Net Income | $-11.2M | $-11.2M | $-11.6M | $-10.8M | $-6.7M |
| EBITDA | $-9.9M | $-9.9M | $-10.3M | $-9.8M | $-6.2M |
| EPS | -0.01 | -0.01 | -0.04 | -0.07 | -0.07 |
| Gross Margin | 47.7% | 47.7% | 45.4% | 52.2% | 75.3% |
| Operating Margin | -981.5% | -981.5% | -1886.5% | -1993.7% | -5585.1% |
| Net Margin | -1018.5% | -1018.5% | -1818.7% | -2122.7% | -4357.1% |
| Balance Sheet | |||||
| Debt/Equity | 4.58 | 4.58 | 1.32 | 1.06 | 2.37 |
| Current Ratio | 0.88 | 0.88 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.8M | $-7.8M | $-10.8M | $-9.0M | $-6.1M |
| Returns | |||||
| ROE | -999.4% | -999.4% | -265.4% | -178.8% | -259.3% |
| Valuation | |||||
| P/B | 229.94 | 229.94 | 194.82 | 974.28 | 692.48 |
| Growth & Yield | |||||
| Revenue Growth | 72.2% | 72.2% | 24.7% | 231.2% | — |
| EPS Growth | 82.2% | 82.2% | 38.4% | -9.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-58.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -0.01
Residual
-58.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.